Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the aromatase inhibitor anastrozole plus the selective estrogen-receptor down-regulator fulvestrant, as compared with anastrozole alone, as first-line therapy. We now report final survival outcomes. METHODS: We randomly assigned patients to receive either anastrozole or fulvestrant plus anastrozole. Randomization was stratified according to adjuvant tamoxifen use. Analysis of survival was performed by means of two-sided stratified log-rank tests and Cox regression. Efficacy and safety were compared between the two groups, both overall and in subgroups. RESULTS: Of 707 patients who had undergone randomization, 694 had data available for analysis. The combination-therapy group had 247 deaths among 349 women (71%) and a median overall survival of 49.8 months, as compared with 261 deaths among 345 women (76%) and a median overall survival of 42.0 months in the anastrozole-alone group, a significant difference (hazard ratio for death, 0.82; 95% confidence interval [CI], 0.69 to 0.98; P = 0.03 by the log-rank test). In a subgroup analysis of the two strata, overall survival among women who had not received tamoxifen previously was longer with the combination therapy than with anastrozole alone (median, 52.2 months and 40.3 months, respectively; hazard ratio, 0.73; 95% CI, 0.58 to 0.92); among women who had received tamoxifen previously, overall survival was similar in the two groups (median, 48.2 months and 43.5 months, respectively; hazard ratio, 0.97; 95% CI, 0.74 to 1.27) (P = 0.09 for interaction). The incidence of long-term toxic effects of grade 3 to 5 was similar in the two groups. Approximately 45% of the patients in the anastrozole-alone group crossed over to receive fulvestrant. CONCLUSIONS: The addition of fulvestrant to anastrozole was associated with increased long-term survival as compared with anastrozole alone, despite substantial crossover to fulvestrant after progression during therapy with anastrozole alone. The results suggest that the benefit was particularly notable in patients without previous exposure to adjuvant endocrine therapy. (Funded by the National Cancer Institute and AstraZeneca; ClinicalTrials.gov number, NCT00075764.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“as well as impressive median survival to date (63.9 months) among women with HR-positive, HER2-negative advanced breast cancer. 16,20,22-29”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [28]
Citations
Cites
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636
Robertson, J. F. R., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., Shparyk, Y., Cardona-Huerta, S., Cheung, K.-L., Philco-Salas, M. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32389-3 · Cited by 582
Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Lew, D. L., Hayes, D. F., Gralow, J. R., Livingston, R. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201622 · Cited by 371
Self-citation
Cited by
Items 101–125 of 125
Ribociclib plus endokrine Therapie verbessert OS in der Prä-/Perimenopause
Krug, D. A., Fabian, A., Dunst, J., & Bauerschlag, D. (2020) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-020-8098-0
Untch, M., Würstlein, R., Lüftner, D., Haidinger, R., Fasching, P. A., Augustin, D., Briest, S., Ettl, J., Forster, F. M. C., Kurbacher, C. M., et al. (2020) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1205-4313
Krug, D. A., Fabian, A., & Dunst, J. (2020) · Strahlentherapie und Onkologie · doi:10.1007/s00066-019-01574-y
The Systemic Exclusion of Native Americans from Cancer Clinical Trials
Cayatineto, H. W., Clyde, C. S., Yazzie, G. A., Selassie, G., & de Soto, J. A. (2021) · Research Review · doi:10.52845/jmrhs/2021-4-8-4
Mikhael, F., & Santharam, R. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3897790
Bezerra, P. H. A. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2020.tde-21092021-054801
Treatment of Metastatic Breast Cancer: Endocrine Therapy
Şen, F., & Aydıner, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-16792-9_30
Vaid, A. K., Deshmukh, C. D., Rohatgi, N., & Ghosh, J. (2022) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_30_21
Metastatic and Secondary Orbital Tumors
Lauer, S. A. (2020) · Springer eBooks · doi:10.1007/978-3-319-90495-5_70-1
Tripathy, D., Makhnoon, S., Arun, B. K., Şahin, A. A., Kettner, N. M., Damodaran, S., Keyomarsi, K., Yang, W. T., Hunt, K. K., Clemens, M. W., et al. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm109.pub2
Espié, M., Bonnet-Bensimon, C., de Castelbajac, V., Cuvier, C., Giacchetti, S., & Teixeira, L. (2022) · EMC - Ginecología-Obstetricia · doi:10.1016/s1283-081x(22)46717-8 · Cited by 1
Ziobro, M., & Grela-Wojewoda, A. (2023) · Biomedicines · doi:10.3390/biomedicines11020510 · Cited by 3
Paoletti, C., Barlow, W. E., Cobain, E. F., Bergqvist, M., Mehta, R. S., Gralow, J. R., Hortobágyi, G. N., Albain, K. S., Pusztai, L., Sharma, P., et al. (2023) · doi:10.1158/1078-0432.c.6530384.v1
Self-citationPaoletti, C., Barlow, W. E., Cobain, E. F., Bergqvist, M., Mehta, R. S., Gralow, J. R., Hortobágyi, G. N., Albain, K. S., Pusztai, L., Sharma, P., et al. (2023) · doi:10.1158/1078-0432.c.6530384
Self-citationTolaney, S. M., Im, Y., Calvo, E., Lu, Y., Hamilton, E. P., Forero, A., Bachelot, T., Maur, M., Fasolo, A., Tiedt, R., et al. (2023) · doi:10.1158/1078-0432.c.6530064
Tolaney, S. M., Im, Y., Calvo, E., Lu, Y., Hamilton, E. P., Forero, A., Bachelot, T., Maur, M., Fasolo, A., Tiedt, R., et al. (2023) · doi:10.1158/1078-0432.c.6530064.v1
Bielo, L. B., Natangelo, S., Katrini, J., Trapani, D., & Curigliano, G. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2244870
“In clinical practice, the combination of SERD and aromatase inhibitors demonstrated to increase patient survival, supporting this hypothesis [15].”
BackgroundShao, H., Zhao, M., Guan, A.-J., Shao, T., Zhou, D., Yu, G., & Tang, W. (2024) · Figshare · doi:10.6084/m9.figshare.24987711
Shao, H., Zhao, M., Guan, A.-J., Shao, T., Zhou, D., Yu, G., & Tang, W. (2024) · Figshare · doi:10.6084/m9.figshare.24987922
Additional file 1 of Reduction in number to treat versus number needed to treat
Zhang, C., & Yin, G. (2021) · Figshare · doi:10.6084/m9.figshare.14189799
Plasticité cellulaire et initiation tumorale dans le modèle du cancer du sein
Blander, H. D. (2020) · theses.fr (ABES) · doi:10.70675/c6b4eda8z19a5z4b3dzb7d9zacc5fd814b21
The role of PRMT5-mediated methylation of steroid receptor in breast Cancer
Pham, T. H. (2022) · theses.fr (ABES) · doi:10.70675/f6e3d282z871dz4ffaz87bazb04f22d60d50 · Cited by 1
Etessami, J. D., Valenza, C., Giachetti, P. P. M. B., Crimini, E., Ferraro, E., Marra, A., Belli, C., Minchella, I., Zagami, P., Curigliano, G., et al. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2678481 · Cited by 1
Wigston, L., Morris, A., Lok, S. W., Baron-Hay, S. E., BOER, R. D., Boyle, F. M., Collins, I. M., Cuff, K. E., Gately, L., Georgiou, C. L., et al. (2026) · Internal Medicine Journal · doi:10.1111/imj.70544
Lucaciu, R. L., Hangan, A. C., Oprean, L. S., & Procopciuc, L. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198619 · Cited by 1
Metadata
- Authors
- Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Lew, D. L., Hayes, D. F., Gralow, J. R., Linden, H. M., Livingston, R. B., & Hortobagyi, G. N.
- Affiliations
- Seattle Cancer Care Alliance (US)
- From the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange (R.S.M.); the SWOG Statistics and Data Management Center (W.E.B., D.L.L.) and Seattle Cancer Care Alliance and University of Washington Medical Center (J.R.G., H.M.L.) — both in Seattle; Loyola University Chicago Stritch School of Medicine, Maywood, IL (K.S.A.); London Health Sciences Centre and the National Cancer Institute of Canada Clinical Trials Group, London, ON, Canada (T.A.V.); the Cancer...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-28
- Volume
- 380
- Issue
- 13
- Pages
- 1226-1234
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6885383
- OpenAlex
- W2925092419
- Cited by
- 126
- References
- 16
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 15 · 2023: 19 · 2022: 17 · 2021: 18 · 2020: 28 · 2019: 19
- FWCI
- 15.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UA Campus Repository (The University of Arizona) (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute of the National Institutes of Health (CA180888, CA180819, CA180863, CA189808, CA180801,)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- fulvestrant, anastrozole, metastatic breast cancer, hormone receptor-positive breast cancer, aromatase inhibitors, overall survival, adjuvant tamoxifen, first-line therapy, postmenopausal women, treatment toxicity, progression-free survival, subgroup analysis, adjuvant endocrine therapy, adjuvant chemotherapy
- MeSH terms
- Fulvestrant, Anastrozole, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Metastasis, Postmenopause, Cross-Over Studies, Aromatase Inhibitors, Kaplan-Meier Estimate, Estrogen Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.